Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis.

Polyethylene glycol interferon alpha (PEG-IFN-α) is the most frequently used pharmacotherapeutic approach in patients infected with hepatitis B virus (HBV). Numerous studies have reported that genetic polymorphisms are related to the therapeutic efficacy of PEG-IFN-α, but the results are inconsistent. The present meta-analysis aimed to analyze the association between genetic polymorphisms and the prognosis of patients with chronic hepatitis B (CHB) treated with PEG-IFN-α to inform clinical practice.

Progress in the Research of Plasminogen Activator Inhibitor Type-2.

Plasminogen activator inhibitor type-2 (PAI-2) inhibits urokinase type plasminogen activator (u-PA) most specifically and high efficiently, following the mechanism of serine proteinase inhibitor (serpin) superfamily. PAI-2 plays a very important role in vivo there are, however, two conflicting views on the role of PAI-2 in cancer. Tissue-type plasminogen activator, vitronectin, transglutaminases, fibrin and many other molecules can interact with PAI-2.